Pharmacological characterization of head and neck cancer in ex-vivo tests;Pharmakologische Charakterisierung von Kopf-Hals-Tumoren in Ex-vivo-Tests

HNO

Volumn 59, Issue 9, 2011, Pages 866-873

  Wichmann, G ^a   Dietz, A ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Cell culture; Chemoresponse test; Head and neck; Predictive assay; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; CANCER STAGING; DISEASE COURSE; DRUG RESISTANCE; DRUG SCREENING; HEAD AND NECK TUMOR; HUMAN; METHODOLOGY; PATHOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 80052286503     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-011-2362-4     Document Type: Review

References (31)

1. Dietz A, Boehm A, Mozet C et al (2008) Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 265(Suppl 1): S3-S12.
2. Weber A, Langhanki L, Sommerer F et al (2003) Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22: 4757-4759.
3. Dutta PR, Maity A (2007) Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254(2): 165-177.
4. Cullen KJ, Schumaker L, Nikitakis N et al (2009) beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol 27(36): 6222-6228.
5. Miyamoto H, Murakami T, Tsuchida K et al (2004) Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28: 38-44.
6. Schrag D, Garewal HS, Burstein HJ et al (2004) ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays. American Society of Clinical Oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22(17): 3631-3638.
7. Granzow C, Kopun M, Heuser M et al (2004) Chemoresistance of human lung tumor stromal cells. Amer Assn Cancer Res 95th Annual Meeting Proc Suppl. abstract LB-82.
8. Dollner R, Granzow C, Helmke BM et al (2004) The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24: 325-331.
9. Zhang S, Balch C, Chan MW (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.
10. Mosmann T (1983) A rapid colorimetric assay for cellular growth and cytotoxicity assays. J Immunol Methods 65: 55-63.
11. Nakashima T, Maehra Y, Kohnoe S et al (1990) Histologic differentiation and chemosensitivity of human head and neck squamous cell carcinoma. Head Neck 12: 406-410.
12. Schroyens W, Tueni E, Dodion P et al (1990) Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer. Eur J Cancer 26: 834-838.
13. Michalski CW, Erkan M, Sauliunaite D et al (2008) Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer 99(5): 760-767.
14. Neubauer H, Stefanova M, Solomayer E et al (2008) Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res 28: 949-955.
15. Elprana D, Schwachofer J, Kuijpers W et al (1987) In vitro chemosensitivity testing of squamous cell carcinoma of the head neck. Acta Otolaryngol 103: 529-536.
16. Kern DH, Drogemuller CR, Kennedy MC et al (1985) Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res 45: 5436-5441.
17. Dietz A, Tschöp K, Wichmann G, Granzow C (2009) Method and kit for the ex vivo evaluation of the response of a tumor to conditions to be tested. Patent Cooperation Treaty (PCT) WO 2009/124997 A1.
18. Horn IS, Wichmann G, Mozet C et al (2010) Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse. Cancer Chemother Pharmacol 65(6): 1153-1163.
19. Wichmann G, Horn IS, Boehm A et al (2009) Single tissue samples from head and neck squamous cell carcinomas are representative regarding the entire tumor's chemosensitivity to cisplatin and docetaxel. Onkologie 32(5): 264-272.
20. Dietz A, Boehm A, Horn IS et al (2010) Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol 267(4): 483-494.
21. Dietz A, Boehm A, Reiche A et al (2010) Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay. J Clin Oncol 28: 15 s (suppl; abstr 5572).
22. Singh B, Li R, Xu L et al (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24: 437-442.
23. Mikos AG, Sarakinos G, Leite SM et al (1993) Laminated three-dimensional biodegradable foams for use in tissue engineering. Biomaterials 14: 323-330.
24. Temenoff JS, Mikos AG (1993) Injectable biodegradable materials for orthopedic tissue engineering. Biomaterials 21: 2405-2412.
25. Bokhari M, Carnachan RJ, Cameron NR, Przyborski SA (2007) Culture of HepG2 liver cells on three dimensional polystyren scaffolds enhances cell structure and function during toxicological challenge. J Anat 211: 567-576.
26. Dasha A, Inman W, Hoffmaster K et al (2009) Liver tissue engineering in the evaluation of drug safety. Exp Opin Drug Metab Toxicol 5: 1159-1174.
27. Maltman DJ, Przyborski SA (2010) Developments in three-dimensional cell culture technology aimed at improving the accuracy of in vitro analyses. Biochem Soc Trans 38: 1072-1075.
28. Nitsch R, Bechmann I, Deisz RA et al (2000) Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356(9232): 827-828.
29. Vistejnova L, Dvorakova J, Hasova M et al (2009) The comparison of impedance-based method of cell proliferation monitoring with commonly used metabolic-based techniques. Neuro Endocrinol Lett 30(Suppl 1): 121-127.
30. Ke N, Wang X, Xu X, Abassi YA (2011) The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol 740: 33-43.
31. Sant M, Allemani C, Santaquilani M et al (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45(6): 931-991.